Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323652 | 1.00 | IDO1 (0.50) | IDO1HTR2ASIGMAR1PAMMAOB | |
| SCHEMBL1829832 | 0.94 | IDO1 (0.48) | IDO1HTR2ASIGMAR1PAMMAOB | |
| SCHEMBL1829833 | 0.94 | IDO1 (0.48) | IDO1HTR2ASIGMAR1PAMMAOB | |
| SCHEMBL7915166 | 0.92 | IDO1 (0.47) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL7901409 | 0.92 | IDO1 (0.47) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL28946124 | 0.92 | IDO1 (0.47) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL1880845 | 0.92 | IDO1 (0.47) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL1368774 | 0.92 | IDO1 (0.47) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL7836247 | 0.90 | IDO1 (0.46) | IDO1HTR2ASIGMAR1PAMMAOA | |
| SCHEMBL11587602 | 0.89 | TNNC1 (0.38) | IDO1HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114084-A1 | Methods for Preparing Ruthenium Carbene Complexes and Precursors Thereto | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2017-04-27 | — | — | US | disclosed |
| US-8399594-B2 | Blocked-isocyanate silicone resins | DOW CORNING CORPORATION (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2102286-B1 | BLOCKED ISOCYANATE SILICONE RESINS | DOW CORNING (US) | 2011-05-11 | — | — | EP | disclosed |
| US-20100093902-A1 | Blocked-Isocyanate Silicone Resins | DOW CORNING CORPORATION | 2010-04-15 | — | — | US | disclosed |
| EP-2102286-A1 | BLOCKED ISOCYANATE SILICONE RESINS | Dow Corning Corporation (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008088492-A1 | BLOCKED ISOCYANATE SILICONE RESINS | DOW CORNING CORPORATRION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20070167587-A1 | Process for producing polymer with functional end | KURARAY CO., LTD. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1721912-A1 | PROCESS FOR PRODUCING POLYMER WITH FUNCTIONAL END | KURARAY CO., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114084-A1 | Methods for Preparing Ruthenium Carbene Complexes and Precursors Thereto | AVPR1B, PRLHR, AVPR2 | IDO1 1930/4885HTR2A 2411/4885SIGMAR1 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.